REGORAFENIB |
BAY-734506 MONOHYDRATE |
STIVARGA |
BAY-73-4506 |
BAY-734506 |
RÉGORAFÉNIB |
STIVARGA® |
REGORAFENIBUM |
BAY 73-4506 |
chemidplus:755037-03-7 |
drugbank:08896 |
chembl:CHEMBL1946170 |
rxcui:1312397 |
pubchem.compound:11167602 |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Colorectal cancer, Gastrointestinal stromal tumors |
Drug Class | Kinase Inhibitors |
inhibitor (inhibitory) |
Mechanism of Interaction | Discoidin domain-containing receptor 2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | regorafenib, BAY 73-4506 |
Novel drug target | Novel Target |
Notes |
inhibitor (inhibitory) |
Response Type | decreased response |
Approval Status | Preclinical - Cell culture |
Approval Status | Phase II |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase RAF inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | MAP kinase p38 beta inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Indication/Tumor Type | colorectal cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase FRK inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | regorafenib, BAY 73-4506 |
Novel drug target | Established target |
Indication/Tumor Type | colorectal cancer |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Indication/Tumor Type | gastrointestinal stromal tumor |
inhibitor (inhibitory) |
Indication/Tumor Type | breast cancer |
Approval Status | Preclinical - Cell line xenograft |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Fibroblast growth factor receptor 2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Fibroblast growth factor receptor 1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase ABL inhibitor |
Direct Interaction | yes |
REGORAFENIB | Generic Name |
STIVARGA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Colorectal cancer, Gastrointestinal stromal tumors |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
FDA Approval | not approved |
REGORAFENIB | Primary Drug Name |
REGORAFENIB | Drug Generic Name |
STIVARGA | Drug Trade Name |
CHEMBL1946170 | ChEMBL Drug ID |
D09GDD | TTD Drug ID |